EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

mefenamic acid
anthranilic acid, N-2,3-xylyl-

Supplier Sponsors

Name:2-(2,3-dimethylanilino)benzoic acid
CAS Number: 61-68-7Picture of molecule3D/inchi
ECHA EINECS - REACH Pre-Reg:200-513-1
FDA UNII: 367589PJ2C
Nikkaji Web:J2.344B
Beilstein Number:2216243
MDL:MFCD00051721
XlogP3:5.10 (est)
Molecular Weight:241.28995000
Formula:C15 H15 N O2
BioActivity Summary:listing
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:pharmaceuticals / chemical synthisis
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 
Physical Properties:
Assay: 95.00 to 100.00
Food Chemicals Codex Listed: No
Melting Point: 230.00 °C. @ 760.00 mm Hg
Boiling Point: 398.80 °C. @ 760.00 mm Hg (est)
Flash Point: 383.00 °F. TCC ( 195.00 °C. ) (est)
logP (o/w): 5.120
Soluble in:
 water, 20 mg/L @ 30 °C (exp)
 
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
None found
 
Suppliers:
BOC Sciences
For experimental / research use only.
Mefenamic Acid
Odor: characteristic
Use: A competitive inhibitor of COX-1 and COX-2
Glentham Life Sciences
Mefenamic acid
Kingchem Laboratories
Mefenamic Acid
Santa Cruz Biotechnology
For experimental / research use only.
Mefenamic Acid ≥99%
Sigma-Aldrich: Sigma
For experimental / research use only.
Mefenamic Acid
TCI AMERICA
For experimental / research use only.
Mefenamic Acid >98.0%(T)
 
Safety Information:
Preferred SDS: View
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
intravenous-cat LD50 100 mg/kg
Current Medical Research and Opinion. Vol. 4, Pg. 17, 1976.

oral-man TDLo 14285 ug/kg/3D
British Journal of Clinical Practice. Vol. 49, Pg. 161, 1995.

oral-man TDLo 257 mg/kg/12D-
KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"
British Medical Journal. Vol. 291, Pg. 661, 1985.

oral-man TDLo 840 mg/kg/6W-I
GASTROINTESTINAL: ULCERATION OR BLEEDING FROM LARGE INTESTINE GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
British Medical Journal. Vol. 287, Pg. 1626, 1983.

intramuscular-mouse LD50 400 mg/kg
Pharmaceutical Chemistry Journal Vol. 17, Pg. 353, 1983.

intraperitoneal-mouse LD50 120 mg/kg
Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 36, 1969.

intravenous-mouse LD50 96 mg/kg
Yakugaku Zasshi. Journal of Pharmacy. Vol. 89, Pg. 1392, 1969.

oral-mouse LD50 525 mg/kg
Journal de Pharmacologie. Vol. 2, Pg. 259, 1971.

intraperitoneal-rat LD50 327 mg/kg
Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971.

intravenous-rat LD50 112 mg/kg
Current Medical Research and Opinion. Vol. 4, Pg. 17, 1976.

oral-rat LD50 740 mg/kg
BEHAVIORAL: ATAXIA BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 28, Pg. 99, 1981.

Dermal Toxicity:
subcutaneous-mouse LDLo > 2000 mg/kg
PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1579, 1970.

Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
pharmaceuticals / chemical synthisis
Recommendation for mefenamic acid usage levels up to:
 not for fragrance use.
 
Recommendation for mefenamic acid flavor usage levels up to:
 not for flavor use.
 
Safety References:
EPI System: View
ClinicalTrials.gov:search
Daily Med:search
AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :4044
National Institute of Allergy and Infectious Diseases:Data
WGK Germany:3
2-(2,3-dimethylanilino)benzoic acid
Chemidplus:0000061687
RTECS:CB4550000 for cas# 61-68-7
 
References:
 2-(2,3-dimethylanilino)benzoic acid
NIST Chemistry WebBook:Search Inchi
Pubchem (cid):4044
Pubchem (sid):134971038
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
CHEBI:View
CHEMBL:View
KEGG (GenomeNet):C02168
HMDB (The Human Metabolome Database):Search
Export Tariff Code:2922.49.3700
ChemSpider:View
Wikipedia:View
Formulations/Preparations:
capsules: 250 mg.
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 not found in nature
 
Synonyms:
 acidum mefenamicum
 anthranilic acid, N-(2,3-xylyl)-
 anthranilic acid, N-2,3-xylyl-
 bafameritin-M
 bafhameritin-M
 benzoic acid, 2-((2,3-dimethylphenyl)amino)-
 benzoic acid, 2-(2,3-dimethylphenyl)amino-
 bonabol
 CI-473
 CL 473
 CN 35355
 CN-35355
 coslan
2-(2,3-dimethylanilino)benzoic acid
2-((2,3-dimethylphenyl)amino)benzoic acid
N-(2,3-dimethylphenyl)anthranilic acid
2-diphenylaminecarboxylic acid, 2',3'-dimethyl-
 fenamin
 lysalgo
 mefacit
 mefedolo
 mefenamate
 mephenamic acid
 mephenaminic acid
 methenamic acid
 mycasaal
 namphen
 parkemed
 ponalar
 ponstan
 ponstan forte
 ponstel
 rolan
 tanston
 vialidon
N-(2,3-xylyl)-2-aminobenzoic acid
N-2,3-xylylanthranilic acid
 

Articles:

PubMed:Synthesis, structure and biological activity of nickel(II) complexes with mefenamato and nitrogen-donor ligands.
PubMed:Multi-residue analytical methodology-based liquid chromatography-time-of-flight-mass spectrometry for the analysis of pharmaceutical residues in surface water and effluents from sewage treatment plants and hospitals.
PubMed:The determination of pharmaceutical residues in cooked and uncooked marine bivalves using pressurised liquid extraction, solid-phase extraction and liquid chromatography–tandem mass spectrometry.
PubMed:Validation of a liquid chromatography method for the simultaneous determination of several nonsteroidal anti-inflammatory drugs in human plasma for therapeutic drug monitoring.
PubMed:The determination of pharmaceutical residues in cooked and uncooked marine bivalves using pressurised liquid extraction, solid-phase extraction and liquid chromatography-tandem mass spectrometry.
PubMed:Development and validation of a confirmatory method for the determination of 12 non steroidal anti-inflammatory drugs in milk using liquid chromatography-tandem mass spectrometry.
PubMed:Simultaneous determination of 20 pharmacologically active substances in cow's milk, goat's milk, and human breast milk by gas chromatography-mass spectrometry.
PubMed:A wild blueberry-enriched diet (Vaccinium angustifolium) improves vascular tone in the adult spontaneously hypertensive rat.
PubMed:Confirmatory analysis of non-steroidal anti-inflammatory drugs in bovine milk by high-performance liquid chromatography with fluorescence detection.
PubMed:Dietary enrichment with wild blueberries (Vaccinium angustifolium) affects the vascular reactivity in the aorta of young spontaneously hypertensive rats.
PubMed:Confirmatory identification of sixteen non-steroidal anti-inflammatory drug residues in raw milk by liquid chromatography coupled with ion trap mass spectrometry.
PubMed:Inhibition of sulfotransferases by xenobiotics.
PubMed:Determination of glabridin in human plasma by solid-phase extraction and LC-MS/MS.
PubMed:The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs.
PubMed:[Variance of bioavailability of pharmaceutical preparations and analysis of factors affecting it].
PubMed:In vivo selectivity of nonsteroidal antiinflammatory drugs and gastrointestinal ulcers in rats.
PubMed:[In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats].
PubMed:Experimental renal papillary necrosis in the Syrian hamster.
PubMed:Thromboxane synthesis inhibitors and postprandial jejunal capillary exchange capacity.
PubMed:Effects of food on absorption of mefenamic acid from two commercial capsules differing in bioavailability under the fasting state.
PubMed:Bioavailability of mefenamic acid: influence of food and water intake.
PubMed:The effects of mefenamic acid on postprandial intestinal carbohydrate metabolism.
PubMed:Prostaglandin synthesis inhibition and postprandial intestinal hyperemia.
 
Notes:
a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. it is an inhibitor of cyclooxygenase.
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy